Related Experiment Video
Updated: Jul 10, 2026
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von
Rajiv Arora1, Thomas C Newton, Michael R Nelson
1Department of Allergy/Immunology, Walter Reed Army Medical Center, Washington, DC 20307, USA. rajiv.arora@us.army.mil
Background:
Subcutaneous immunoglobulin (SCIG) is an option for replacement therapy in patients with humoral immune deficiencies.
Objective:
To describe a patient with common variable immunodeficiency (CVID) and von Willebrand disease who tolerated immunoglobulin replacement via the subcutaneous route.
Methods:
An 11-year-old boy receiving monthly intravenous immunoglobulin (IVIG) since 5 years of age presented to an academic medical center after moving to the area. The patient also had a history of von Willebrand disease. He had started receiving IVIG because of recurrent infections and an absent IgG subclass 3. Further immunologic assessment revealed a normal B-cell count, decreased IgM level, and an abnormal response to bacteriophage phiX174. Given these findings and the lack of another cause, the patient was diagnosed as having CVID. Because of difficult intravenous access, a port was placed for IVIG administration in 1999. The initial port was removed because of infectious complications, and a second port was found to be distally displaced in the right atrium, requiring removal.
Results:
Continued difficulties with intravenous access and the potential complications with maintaining a long-term indwelling catheter prompted consideration of alternative methods for immunoglobulin administration. After removal of the port, the patient was prescribed weekly SCIG infusions. He tolerated the infusions well without bleeding complications related to the von Willebrand disease and was able to transition to home infusions.
Conclusions:
SCIG was well tolerated by a pediatric patient with CVID and von Willebrand disease without any significant bleeding complications.
Related Concept Videos
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
01:15Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...